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Summary We have screened 33 ovarian tumours of various grades and stages for loss of heterozygosity
(LOH) of markers on chromosome 9. LOH was detected in 26 cases (79%). Eleven tumours (33%) showed
LOH of all informative markers. The remaining 15 cases had partial deletions. Of these, six (18%) had losses
on 9p only, three (9%) had LOH confined to 9q and six (18%) had losses on both chromosome arms, four of
which had a region of retention of heterozygosity in between. There was no association between tumour grade,
stage or histopathology and any losses. High-density deletion mapping was carried out in 12 selected cases that
had partial deletions of 9p and/or 9q. The deleted region on 9p incuded the cyclin-dependent kinase inhibitor 2
(CDKN2) locus and one tumour was found to have a homozygous deletion of CDKN2. LOH on 9q extended
over a larger region. We found evidence for two regions of deletion on 9q, one at 9q34 and the other
encompassing the nevoid basal cell carcinoma (Gorlin) syndrome locus on proximal 9q.
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Every year 4500 new cases of epithelial ovarian cancer are
reported in the UK, representing the fourth most common
cancer in women. Studies at the chromosomal and molecular
levels have revealed deletion of many different chromosomes
(Cliby et al., 1993; Osborne and Leech, 1994a). This may
indicate that several different tumour-suppressor genes play a
role in the development of ovarian cancer. However, it is also
possible that the various forms of ovarian tumours have a
different molecular basis, i.e. the involvement of specific
suppressor genes may result in a tumour of a certain
pathology or prognosis.
The involvement of chromosome 9 in ovarian cancer was
first reported by Cliby et al. (1993). These workers found 9q
to be deleted in 54% of tumours studied. This high incidence
has subsequently been confirmed (Osborne and Leech,
1994a, b) but to date, no detailed deletion mapping has
been reported. In this study we have assessed the frequency
of deletion on both arms of chromosome 9 in a series of
ovarian tumours. We have also screened this series of
tumours for loss of heterozygosity (LOH) of microsatellite




Fresh primary ovarian tumour tissue from 33 patients was
transferred directly to dry ice or liquid nitrogen and stored at
-70°C until processing. Heparinised blood was obtained
from these patients post-operatively and served as a source of
constitutional DNA. FIGO staging, histopathology and
differentiation state were determined. DNA from fresh
frozen tissue was extracted by a standard technique as
described previously (Eccies et al., 1990).
Analysis of LOH using microsatellite polymorphisms
Twenty-three microsatellite markers were used. These are
shown in linkage order in Figure 1. Primer sequences were
obtained from the Genome Data Base. Primers were end-
labelled using T4 polynucleotide kinase (Cambridge
Bioscience, Cambridge, UK). Polymerase chain reactions
(PCRs) and electrophoresis were carried out as described
previously (Keen and Knowles, 1994). The relative intensity
of signal from each allele amplified from tumour DNA was
compared with those amplified from leucocyte DNA. LOH
was scored by eye and cases with >40% reduction in
intensity of signal of one allele were scored as LOH. We have
used the term LOH rather than allele imbalance since most
tumours with alterations in relative intensity showed clear
loss of signal from one allele. This does not preclude the
possibility that allelic gain may be present in some cases.
Quantitative PCR
Duplex PCR reactions with exons 1 or 2 of the CDKN2 gene
and a fragment of the enolase gene were used to assay for
homozygous deletions. Enolase (chromosome 12p) served as
an internal control. The primer sequences and PCR
conditions are as previously described (Willliamson et al.,
1995). Dried gels were subjected to phosphorimager analysis
(Molecular Dynamics, Sunnyvale, CA, USA).
Results
Thirty-three ovarian tumours of various grades and stages
were examined for LOH of chromosome 9 using a series of
microsatellite markers. The relative position of these loci on
the chromosome 9 linkage map and their approximate
physical locations are shown in Figure 1 (Povey et al.,
1994). Screening was performed using 11 markers on 9p and
12 markers on 9q. LOH was detected in 26 cases (79%).
Eleven cases (33%) showed LOH of all informative markers.
This probably reflects aneusomy of chromosome 9. The
remaining 15 tumours had partial deletions. Six (18%)
showed LOH of all or some markers on 9p while retaining
heterozygosity at all informative markers on 9q. In three
tumours (9%) LOH was scored for markers on 9q only and
six tumours (18%) displayed losses on both arms, four of
which had a clear region of retention in between. In total,
70% tumours had 9p losses and 61% had 9q losses.
Histopathological grading and staging of the tumours is
shown in Table I. There was no evidence for an association
between particular losses and tumour histology, grade or
stage.
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Figure 1 Patterns of LOH in 12 ovarian carcinomas. The linkage order and the relative cytogenetic locations of the microsatellite
markers are from Povey et al. (1994). W, Retention of heterozygosity; _, loss of heterozygosity; M, not informative; [
homozygous deletion; M, not done. The arrow marks the position of the centromere. The solid bars represent common regions of
deletion.
The pattern of LOH in 12 selected tumours with partial
deletions on 9p and/or 9q is illustrated in Figure 1. 9p was
deleted to various extents including terminal and interstitial
deletions. The common region of deletion was at 9p2l and
included markers between D9S126 and D9S736. Tumour 2
was found to have an apparent retention of heterozygosity at
the D9S171 locus with LOH on either side. The signal for
D9S171 from the tumour template was very faint compared
with that from the blood, indicating the possibility of a
homozygous deletion with some signal generated by stromal
contamination of the tumour sample. We have previously
reported similar findings and showed by duplex quantitative
PCR that these represent homozygous deletions (Devlin et
al., 1994). A candidate tumour-suppressor gene, CDKN2, has
been mapped within this region (Kamb et al., 1994).
Quantitative PCRs were therefore carried out to investigate
whether CDKN2 was homozygously deleted in tumour 2.
Duplex PCRs were set up using primers for exon 1 or exon 2
of CDKN2 and enolase as an internal control. Enolase has
been mapped to chromosome 12p, a chromosome arm not
found to be involved in ovarian cancer (Cliby et al., 1993;
Osborne and Leech, 1994a). Tumour 2 was found to have a
homozygous deletion in both exons 1 and 2 of CDKN2.
Figure 2 illustrates the results of duplex PCR reactions using
enolase and exon 2 primers.
The losses on 9q were large and spanned all or most of the
q arm. Seven deletions involved the distal part of 9q. Four
tumours (7,8,10,11) had breakpoints distal to D9S12 and in
one of these, tumour 7, a breakpoint distal to HXB at 9q32
was identified (Figure 2). In tumours 4, 5 and 9 the 9q
deletions were large, which may indicate that more than one
gene is targeted. Tumour 9 had an interstitial deletion
between IFNA on 9p and HXB. The status of CDKN2 in
this tumour was assessed using duplex PCRs and quantita-
tion using phosphorimager analysis. The intensities of the
signals from enolase and CDKN2 were identical in the blood
and tumour lanes. Thus, it was shown that CDKN2 was
retained and therefore not the target of deletion.
Discussion
In this study we assessed the frequency of deletions on both
arms of chromosome 9 in a series of ovarian tumours and
demonstrated that deletions of both 9p and 9q occurred at
high frequency. LOH of one or more markers was detected in
79% cases, of which 70% involved 9p and 61% involved 9q.
We have confirmed the frequent involvement of 9q deletions
in ovarian tumours. The proportion of 9q losses is similar to
that reported in two previous studies (Cliby et al., 1993;
Schultz et al., 1995), 54% and 56% respectively. However, we
found a higher frequency of 9p LOH (70%) than has been
reported previously. Three earlier studies found 30-37% 9p
LOH (Cliby et al., 1993; Chenevix-Trench et al., 1994;
Osborne and Leech, 1994a). Schultz et al. (1995) reported
losses on 9p in only 5/40 (13%) ovarian tumours and only
two ofthese also had losses on 9q. In the present study, LOH
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Table I Tumour histopathology and chromosome 9 LOH
Chromosome 9 status Histology Stagea Gradeb Tumour
Retention Mucinous adenocarcinoma 3 NK 13
Retention Mucinous adenoma 1 WD 14
Retention Serous adenocarcinoma 4 PD 15
Retention Mucinous adenocarcinoma IA MD 16
Retention Mucinous adenocarcinoma 1A WD 17
Retention Serous borderline 3 NK 18
Retention Serous adenocarcinoma 4 PD 19
LOH 9p only Serous adenocarcinoma 3 MD 1
LOH 9p only Mucinous borderline IA NK 2
LOH 9p only Endometrioid adenocarcinoma IA MD 3
LOH 9p only Serous adenocarcinoma 3 PD 20
LOH 9p only Serous adenocarcinoma 3B PD 21
LOH 9p only Endometrioid adenocarcinoma IA PD 22
LOH 9q only Serous adenocarcinoma 3 PD 10
LOH 9q only Serous adenocarcinoma 3 MD 11
LOH 9q only Mucinous adenocarcinoma IA MD 12
LOH 9p and q Mucinous adenocarcinoma IA MD 4
LOH 9p and q Serous adenocarcinoma 3B PD 5
LOH 9p and q Granulosa IA PD 6
LOH 9p and q Serous adenocarcinoma 3 PD 7
LOH 9p and q Serous adenocarcinoma 3 MD 8
LOH 9p and q Endometrioid adenocarcinoma 1 WD 9
LOH 9p and q Mesonephroid adenocarcinoma IC MD 23
LOH 9p and q Serous adenocarcinoma 3 PD 24
LOH 9p and q Serous adenocarcinoma 3 PD 25
LOH 9p and q Serous adenocarcinoma 3 PD 26
LOH 9p and q Endometrioid adenocarcinoma IA PD 27
LOH 9p and q Serous adenocarcinoma 3 PD 28
LOH 9p and q Serous adenocarcinoma 3 MD 29
LOH 9p and q Serous adenocarcinoma 3 PD 30
LOH 9p and q Serous adenocarcinoma 3 PD 31
LOH 9p and q Serous adenocarcinoma IC PD 32
LOH 9p and q Teratoma 1 NK 33
aTumours were stagedaccording to FIGO classification.bTumours were graded as beingeitherpoorly differentiated
(PD); moderately differentiated (MD); or well differentiated (WD). NK, information not known.
Tumour 2
BT











Figure 2 Autoradiographs showing the pattern of homozygous
deletion and LOH in tumours 2, 7 and 9. Duplex PCR reactions
were carried out in tumour 2 with exon 2 of CDKN2 (pl6) and
enolase.
tumours but in addition we identified a significant number of
tumours with LOH of 9p only or defined deletion of 9p and
9q. The reason for the differences in the apparent frequency
of 9p LOH is not clear.
The common region of deletion on 9p was between
D9S126 and D9S736 at 9p21. This region of 9p has been
reported to be deleted in several tumour types, e.g. bladder
(Cairns et al., 1994; Devlin et al., 1994), melanoma (Fountain
et al., 1992) and head and neck (van der Riet et al., 1994).
LOH of9p2l has been reported previously in 32% of ovarian
tumours (Chenevix-Trench et al., 1994). The CDKN2 gene
has recently been identified as a candidate tumour suppressor
within this region (Kamb et al., 1994; Nobori et al., 1994)
and encodes cyclin-dependent kinase inhibitor 2 (pl6). This
gene has been reported to be homozygously deleted in
various tumour cell lines, including ovarian (Kamb et al.,
1994). Tumour 2 was found to have a homozygous deletion
of exons 1 and 2 of the CDKN2 gene. Our finding of one
deletion in 33 tumours (3%) is likely to represent an
underestimate of the frequency of homozygous deletion of
CDKN2 since all tumours were not critically evaluated by
quantitative PCR. Careful assessment of the frequency of
CDKN2 deletion in ovarian carcinoma is now needed.
The deletions on 9q involved larger regions. However, on
the basis of the pattern of LOH we have identified two
possible targets of deletion on 9q. Four tumours (7,8,10,11)
define a region of loss distal to D9S12. Based on information
from one case, tumour 7, it is possible to further refine the
location of one of these putative tumour-suppressor gene loci
as distal to HXB at 9q32. However, this must now be
confirmed in a larger series of tumours. Tumour 9 had a large
interstitial deletion between IFNA on 9p21 and HXB. The
CDKN2 gene was found to be retained and so was not the
target of deletion. Thus, in this tumour there is evidence for
another tumour-suppressor gene(s) on proximal 9p or
proximal 9q. If the targeted region is on 9q this would
include the nevoid basal cell carcinoma (Gorlin) syndrome
gene at 9q22 (Povey et al., 1994). This region is deleted in
422Chromosome 9 deletion in ovarian cancer
J Devlin et a! X
423
sporadic basal cell carcinomas of the skin as well as in
familial cases (Quinn et al., 1994); Shanley et al., 1995). The
common region of deletion in these tumours is well-defined
and many microsatellite markers are available to allow more
detailed mapping in ovarian cancer. In a recent report,
Schultz et al. (1995) also defined two regions of deletion on
9q, a small region of loss on 9q31 between D9S127 and
D9S53 and a larger region spanning HXB to ASS (a locus
very close to ABL) at 9q32-34. Both regions overlap the
regions reported here.
9q deletion has also been reported in other tumour types
including bladder (Keen and Knowles, 1994), small-cell lung
cancer (SCLC) (Merlo et al., 1994) and renal tumours (Cairns
et al., 1995). In ovarian tumours the region of deletion distal
to HXB is coincident with that reported in a renal tumour
(Cairns et al., 1995) and also encompasses the tuberous
sclerosis locus (TSCI) at 9q34 (Povey et al., 1994). LOH at
9q34 has recently been described in a tumour from a patient
with TSC, providing evidence that this gene may act as a
tumour-suppressor gene (Carbonara et al., 1994). Both the
present study and a recent study of 9q deletions in bladder
cancer (Habuchi et al., 1995) indicate that more than one
tumour-suppressor gene is present on chromosome 9q.
Further detailed deletion mapping studies in other tumours
with 9q LOH will determine the relative frequency of
involvement of these loci in human cancer. Identification of
the genes concerned should significantly contribute to our
understanding of many epithelial cancers.
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